Cargando…

The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome

The orexin system regulates feeding, nutrient metabolism and energy homeostasis. Acute pharmacological blockade of orexin receptor 1 (OXR-1) in rodents induces satiety and reduces normal and palatable food intake. Genetic OXR-1 deletion in mice improves hyperglycemia under high-fat (HF) diet conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiner, Michel A., Sciarretta, Carla, Pasquali, Anne, Jenck, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874552/
https://www.ncbi.nlm.nih.gov/pubmed/24416020
http://dx.doi.org/10.3389/fphar.2013.00165
_version_ 1782297237349466112
author Steiner, Michel A.
Sciarretta, Carla
Pasquali, Anne
Jenck, Francois
author_facet Steiner, Michel A.
Sciarretta, Carla
Pasquali, Anne
Jenck, Francois
author_sort Steiner, Michel A.
collection PubMed
description The orexin system regulates feeding, nutrient metabolism and energy homeostasis. Acute pharmacological blockade of orexin receptor 1 (OXR-1) in rodents induces satiety and reduces normal and palatable food intake. Genetic OXR-1 deletion in mice improves hyperglycemia under high-fat (HF) diet conditions. Here we investigated the effects of chronic treatment with the novel selective OXR-1 antagonist ACT-335827 in a rat model of diet-induced obesity (DIO) associated with metabolic syndrome (MetS). Rats were fed either standard chow (SC) or a cafeteria (CAF) diet comprised of intermittent human snacks and a constant free choice between a HF/sweet (HF/S) diet and SC for 13 weeks. Thereafter the SC group was treated with vehicle (for 4 weeks) and the CAF group was divided into a vehicle and an ACT-335827 treatment group. Energy and water intake, food preference, and indicators of MetS (abdominal obesity, glucose homeostasis, plasma lipids, and blood pressure) were monitored. Hippocampus-dependent memory, which can be impaired by DIO, was assessed. CAF diet fed rats treated with ACT-335827 consumed less of the HF/S diet and more of the SC, but did not change their snack or total kcal intake compared to vehicle-treated rats. ACT-335827 increased water intake and the high-density lipoprotein associated cholesterol proportion of total circulating cholesterol. ACT-335827 slightly increased body weight gain (4% vs. controls) and feed efficiency in the absence of hyperphagia. These effects were not associated with significant changes in the elevated fasting glucose and triglyceride (TG) plasma levels, glucose intolerance, elevated blood pressure, and adiposity due to CAF diet consumption. Neither CAF diet consumption alone nor ACT-335827 affected memory. In conclusion, the main metabolic characteristics associated with DIO and MetS in rats remained unaffected by chronic ACT-335827 treatment, suggesting that pharmacological OXR-1 blockade has minimal impact in this model.
format Online
Article
Text
id pubmed-3874552
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38745522014-01-10 The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome Steiner, Michel A. Sciarretta, Carla Pasquali, Anne Jenck, Francois Front Pharmacol Pharmacology The orexin system regulates feeding, nutrient metabolism and energy homeostasis. Acute pharmacological blockade of orexin receptor 1 (OXR-1) in rodents induces satiety and reduces normal and palatable food intake. Genetic OXR-1 deletion in mice improves hyperglycemia under high-fat (HF) diet conditions. Here we investigated the effects of chronic treatment with the novel selective OXR-1 antagonist ACT-335827 in a rat model of diet-induced obesity (DIO) associated with metabolic syndrome (MetS). Rats were fed either standard chow (SC) or a cafeteria (CAF) diet comprised of intermittent human snacks and a constant free choice between a HF/sweet (HF/S) diet and SC for 13 weeks. Thereafter the SC group was treated with vehicle (for 4 weeks) and the CAF group was divided into a vehicle and an ACT-335827 treatment group. Energy and water intake, food preference, and indicators of MetS (abdominal obesity, glucose homeostasis, plasma lipids, and blood pressure) were monitored. Hippocampus-dependent memory, which can be impaired by DIO, was assessed. CAF diet fed rats treated with ACT-335827 consumed less of the HF/S diet and more of the SC, but did not change their snack or total kcal intake compared to vehicle-treated rats. ACT-335827 increased water intake and the high-density lipoprotein associated cholesterol proportion of total circulating cholesterol. ACT-335827 slightly increased body weight gain (4% vs. controls) and feed efficiency in the absence of hyperphagia. These effects were not associated with significant changes in the elevated fasting glucose and triglyceride (TG) plasma levels, glucose intolerance, elevated blood pressure, and adiposity due to CAF diet consumption. Neither CAF diet consumption alone nor ACT-335827 affected memory. In conclusion, the main metabolic characteristics associated with DIO and MetS in rats remained unaffected by chronic ACT-335827 treatment, suggesting that pharmacological OXR-1 blockade has minimal impact in this model. Frontiers Media S.A. 2013-12-30 /pmc/articles/PMC3874552/ /pubmed/24416020 http://dx.doi.org/10.3389/fphar.2013.00165 Text en Copyright © 2013 Steiner, Sciarretta, Pasquali and Jenck. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Steiner, Michel A.
Sciarretta, Carla
Pasquali, Anne
Jenck, Francois
The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title_full The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title_fullStr The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title_full_unstemmed The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title_short The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
title_sort selective orexin receptor 1 antagonist act-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874552/
https://www.ncbi.nlm.nih.gov/pubmed/24416020
http://dx.doi.org/10.3389/fphar.2013.00165
work_keys_str_mv AT steinermichela theselectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT sciarrettacarla theselectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT pasqualianne theselectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT jenckfrancois theselectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT steinermichela selectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT sciarrettacarla selectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT pasqualianne selectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome
AT jenckfrancois selectiveorexinreceptor1antagonistact335827inaratmodelofdietinducedobesityassociatedwithmetabolicsyndrome